Research progress in therapeutic strategy of human immunodeficiency virus type 1 latenty by targeting Tat
10.13481/j.1671-587X.20250330
- VernacularTitle:以Tat为靶点的人类免疫缺陷病毒1型潜伏库治疗策略的研究进展
- Author:
Haobo HU
1
;
Chen HUAN
Author Information
1. 吉林大学第一医院艾滋病与病毒研究所,吉林 长春 130021
- Keywords:
Acquired immunodeficiency syndrome;
Transactivator;
HIV-1 latent reservoir;
"Block-and-lock"strategy;
Functional cure
- From:
Journal of Jilin University(Medicine Edition)
2025;51(3):831-838
- CountryChina
- Language:Chinese
-
Abstract:
Human immunodeficiency virus type 1(HIV-1)latent reservoirs pose the primary obstacle to curing acquired immunodeficiency syndrome(AIDS).Transactivator(Tat),a regulatory protein encoded by HIV-1,influences the establishment and reactivation of latent reservoirs by promoting viral transcription.Inhibitors targeting Tat protein suppress viral rebound by reducing Tat protein levels and disrupting its transcription-promoting functions.Among the two strategies for treating HIV-1 latent reservoirs,the"block-and-lock"strategy,which is based on Tat protein inhibitors,aims to target HIV-1 proteins or host factors while interfering with histone epigenetic modifications,thereby permanently silencing proviral DNA and maintaining HIV-1 latency even after treatment discontinuation.Tat-related inhibitors such as didehydrocortistatin A(dCA),triptolide,and apalutamide-derived Q308 regulate HIV-1 latency through distinct mechanisms.This review summarizes the regulatory roles of Tat in HIV-1 latency,Tat protein inhibitor-based therapeutic strategies for targeting latent reservoirs,and the mechanisms of action of related inhibitors,with the goal of providing insights for the development of drugs toward achieving functional HIV-1 cure.
